GlassScriptPhysician profile
Auburn Kidd
NPI 1780141200
$4,556.85
in general payments reported to CMS, 2019-2025
23 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.31 · 2022: $80.55 · 2023: $1,472 · 2024: $1,532 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,831 · Education: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,831.08 |
| Education | $571.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $736.79 | 2023-2025 | |
| Abbvie INC. | $689.43 | 2021-2025 | |
| Janssen Biotech, INC. | $518.43 | 2023-2025 | Tremfya |
| Ucb, INC. | $352.56 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $342.54 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $332.12 | 2023-2025 | Ilumya |
| Galderma Laboratories, L.P. | $259.70 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $233.15 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $222.42 | 2023-2025 | Dupixent |
| Incyte Corporation | $155.69 | 2023-2025 | Opzelura |
| Dermavant Sciences, INC. | $131.08 | 2023-2024 | Vtama |
| Leo Pharma INC. | $119.30 | 2023-2024 | Adbry |
| Pfizer INC. | $107.83 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $87.85 | 2023-2025 | Sotyktu |
| Amgen INC. | $46.29 | 2025 | Otezla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $45.52 | 2023-2024 | Proclaim |
| Novo Nordisk INC | $45.48 | 2021 | |
| Organon LLC | $37.96 | 2023-2025 | Hadlima, Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.95 | 2023 | Spevigo |
| Fresenius Kabi USA, LLC | $19.35 | 2024 | Idacio |
| Mallinckrodt Hospital Products INC. | $16.98 | 2024 | Acthar |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.57 | 2023 | Arazlo |
| Takeda Pharmaceuticals U.S.A., INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Auburn Kidd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.